IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results; Data Submitted To FDA Requesting Marketing Authorization To Treat Early-Stage Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical announced the final results of its ICE3 breast cancer cryoablation trial, submitting data to the FDA for marketing authorization to treat early-stage breast cancer. The data, presented at the ASBrS Annual Meeting and awarded the Scientific Impact Award, supports the use of cryoablation for early stage T1 invasive breast cancer with adjuvant hormone therapy. The company anticipates enhanced usage upon approval, citing the availability of a reimbursement code for facility expenses and the cost-effectiveness of its ProSense® cryoablation system.
April 15, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IceCure Medical submits ICE3 trial results for FDA marketing authorization for early-stage breast cancer treatment, indicating potential market expansion and revenue growth.
The submission of the ICE3 trial results to the FDA by IceCure Medical for marketing authorization represents a significant step towards commercializing their cryoablation treatment for early-stage breast cancer. The positive reception of the data at the ASBrS Annual Meeting, coupled with the existing reimbursement code for facility expenses, suggests a strong potential for market adoption and revenue growth upon approval. The company's focus on a minimally-invasive treatment option that is cost-effective adds to the potential for widespread usage, making this a pivotal moment for IceCure Medical.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100